Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease

Inclusion Criteria:

1. Patients older than 20 years accompanying chronic atrial fibrillation with CHADS2score ≥2

2. Patients with coronary artery disease (which requires DES) should receive the 2ndgeneration drug-eluting stent insertion treatment

3. Subjects and their legal representatives must understand the main purpose of thisstudy, agree with relevant provisions, and sign to consent forms approved by IRBs ofeach institution.

4. Subjects should agree with the follow-up studies as (coronary angiography) andtransesophageal echocardiography, etc.

5. Subjects should agree to follow our requests for post-operative follow-up visits.

Exclusion Criteria:

1. Patients showing any hypersensitive reaction or reason for restriction to aspirin,heparin, clopidogrel, or warfarin, or otherwise, susceptible to contrast media, andtherefore, who could not use those drugs and who were pregnant or breast feeding.

2. Comorbidities other than atrial fibrillation that required chronic warfarin use.

3. Patients diagnosed with progressive infection condition or endocarditis.

4. Patients who have been diagnosed with progressive gastric ulcer or uppergastrointestinal bleeding for last 3 months.

5. Hemodynamically unstable patients who needs inotropic supports.

6. Senile dementia patients who have experienced any cerebrovascular accident (CVA) forlast 6 weeks.

7. Patients who have been diagnosed with intracardiac mass, thrombus, or vegetation asechocardiographic findings.

8. Patients diagnosed with severe left ventricular dysfunction (<LVEF 30%).

9. Patients with blood disorder as followings: leucopenia (<WBC 3,000mm3), acute anemia (<Hg 9mg %), Thrombocytopenia (<100,000 platelets/mm3), or any evidence of bleeding orclotting disorders.

10. Patients showing life expectancy less than 12 months because of noncardiaccomorbidities.

11. Patients having severe vein occlusion at femoral vein, ceiling vein, or inferior venacava.

12. A patent foramen ovale with atrial septal aneurysm and right-to-left shunt

13. Symptomatic carotid artery disease

14. Patients with severe valvular heart disease

15. Patients who are currently participating in other clinical trials for any drug ormedical device.